Patient-Specific Factors Impacting Treatment Choices in RCC
Mehmet Asim Bilen, MD, reviews patient-specific factors such as comorbidities, RCC histology, and metastatic status that may factor into treatment decision-making.
Case Presentation 1: Selecting Therapy in Transplant-Ineligible NDMM
Centering discussion on a patient case of transplant-ineligible newly diagnosed multiple myeloma, experts consider how they would approach workup and management.
NDMM Management: Assessing Response and Determining Duration of Therapy
Comprehensive insight on optimizing newly diagnosed multiple myeloma management, ranging from response assessment to use of consolidation and maintenance therapy.
Introduction and CLL Background
May 16th 2022Michael R. Bishop, MD, introduces the 2021 Journal of Clinical Oncology publication, “Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III Trial” and invites Bruce B. Bank, MD, to comment on the typical patients with chronic lymphocytic leukemia (CLL) he sees in his clinical practice.
Adoption of Pediatric-Inspired ALL Regimens by Adult Oncologists
Reem Akel, MD, presents a population-based study on the adoption of pediatric-inspired acute lymphoblastic leukemia (ALL) regimens by adult oncologists.
Remaining Unmet Needs in Frontline Maintenance Therapy and Ongoing Trials for mUC
The panel summarizes unmet needs in frontline maintenance therapy for UC and comments on ongoing trials for novel treatment regimens.
Treatment Options After Progression on Frontline Maintenance Therapy
Petros Grivas, MD, PhD, revisits the patient profile and invites panel members to share recommended treatment options for patients with or without FGFR mutations, who progress after chemotherapy and maintenance avelumab.
Subcutaneous Treatment of Early-Stage HER2+ Breast Cancer During the COVID-19 Pandemic
May 11th 2022Sarah M. Tolaney, MD, MPH, describes her usage of pertuzumab, trastuzumab, and hyaluronidase-zzxf subcutaneous injections in her clinical practice during the COVID-19 pandemic for patients with HER2+ breast cancer.
Strategies for Prevention and Management of Adverse Events
Chung-Han Lee, MD, PhD, provides a commentary on strategies for preventing and managing treatment-related adverse events in metastatic RCC.
Balancing Treatment Efficacy with Toxicity in Metastatic RCC
David Aggen, MD, PhD, describes the challenges of balancing treatment efficacy versus toxicity and tolerability in patients with kidney cancer.
Alina Markova, MD, on Key Findings With Topical Ruxolitinib in Cutaneous Chronic GVHD
May 10th 2022Alina Markova, MD, highlights important findings from a study assessing topical ruxolitinib INCB018424 phosphate 1.5% cream as a treatment for non-sclerotic and superficially sclerotic chronic cutaneous graft-versus-host disease.
Frontline Quadruplet Therapy in NDMM: GMMG-HD7
Shared insight on the GMMG-HD7 study, which utilized a frontline isatuximab-containing quadruplet regimen in patients with newly diagnosed multiple myeloma.